HeartWare VAS for DT Trial

Overview

Status: Active, not recruiting
Keywords: LVAD , Heart Failure , Destination Therapy , Artificial Heart
IRB Number: 00044513
Specialty: Cardiothoracic Surgery
Sub Specialties: Heart Failure

Brief Summary

This is a prospective, randomized, unblinded, multi-center, non-inferiority evaluation of the HeartWare® VAS versus a control group consisting of any FDA-approved LVAD approved for destination therapy. Patients are randomized to HeartWare® VAS or control LVAD in a 2:1 ratio. Each patient receiving the HeartWare® VAS or control LVAD is followed to the primary endpoint at 2 years, with a subsequent follow-up period extending to 5 years post implant.

The HeartWare® Ventricular Assist System (VAS) is intended for use in patients with chronic Stage D or NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy and who are ineligible for cardiac transplantation.

The objective of this study is to compare the safety and effectiveness of the HeartWare® VAS for destination therapy to other FDA-approved LVADs approved for destination therapy in patients with end-stage heart failure who are ineligible for heart transplantation.

The primary endpoint is stroke-free (Modified Rankin Score < 4), survival at 2 years on the originally implanted LVAD.

Secondary endpoints include the incidence of bleeding, incidence of major infections (per INTERMACS definitions), time to death, length of hospitalization and incidence of rehospitalizations, incidence of all device failures and device malfunctions, Health Status improvement, and Functional status improvement.

Safety measures will include the frequency and rates of adverse events, overall and for each specific event, which will be collected throughout LVAD support.

Detailed Description

This is a prospective, randomized, unblinded, multi-center, non-inferiority evaluation of the HeartWare® VAS versus a control group consisting of any FDA-approved LVAD approved for destination therapy. Patients are randomized to HeartWare® VAS or control LVAD in a 2:1 ratio. Each patient receiving the HeartWare® VAS or control LVAD is followed to the primary endpoint at 2 years, with a subsequent follow-up period extending to 5 years post implant.

Principal Investigator: Craig Selzman
Department: Cardiothoracic Divison
Co Investigator:

Contact Information

Name:Erin Davis
Phone: 801-581-5834
Email: erin.davis@hsc.utah.edu

Inclusion Criteria

1. Must be ≥18 years of age at consent
 
2. Body Surface Area (BSA) ≥ 1.2 m2
 
3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient must meet one of the following)
 
a. On optimal medical management, including dietary salt restriction and diuretics, for at least 45 out of the last 60 days and are failing to respond; or
 
b. In Class III or Class IV heart failure for at least 14 days, and dependent on intra aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days
 
4. Left ventricular ejection fraction < or = to 25%
 
5. LVAD implant is intended as destination therapy
 
6. Must be able to receive either the HeartWare® VAS or control LVAD
 
7. Female patients of childbearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives or a combination of condom and spermicide) for the duration of the study.
 
8. The patient or legally authorized representative has signed the informed consent form

Exclusion Criteria

1. Body Mass Index (BMI) > 40
 
2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
 
3. Prior cardiac transplant.
 
4. History of confirmed, untreated abdominal or thoracic aortic aneurysm > 5 cm.
 
5. Cardiothoracic surgery within 30 days of randomization.
 
6. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities as described (Figure 2) in the guidelines published in ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction1;.
 
7. Patients eligible for cardiac transplantation
 
8. On ventilator support for > 72 hours within the four days immediately prior to randomization and implant.
 
9. Pulmonary embolus within three weeks of randomization as documented by computed tomography (CT) scan or nuclear scan.
 
10. Symptomatic cerebrovascular disease, stroke within 180 days of randomization or > 80% stenosis of carotid or cranial vessels.
 
11. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant.
 
12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening/randomization or right atrial pressure > 20 mmHg on multiple inotropes or right ventricular ejection fraction (RVEF) <15% with clinical signs of severe right heart failure (e.g. lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and two inotropic drugs).
 
13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell (WBC) count, hypotension, tachycardia, generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.
 
14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 75,000, INR > 2.0 or PTT > 2.5 times control in the absence of anticoagulation therapy).
 
15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient’s health status.
 
16. Serum creatinine > 3.0 mg/dL within 72 hours of randomization or requiring dialysis or ultrafiltration.
 

17. Specific liver enzymes [AST (SGOT) and ALT (SGPT)] > 3 times upper limit of normal within 72 hours of randomization.

18. A total bilirubin > 3 mg/dl within 72 hours of randomization, or biopsy proven liver cirrhosis or portal hypertension.
 
19. Pulmonary vascular resistance is demonstrated to be unresponsive to pharmacological manipulation and the PVR > 6 Wood units.
 
20. Patients with a mechanical heart valve.
 
21. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy
 
22. History of severe COPD or severe restrictive lung disease (e.g. FEV1 <50%)
 
23. Participation in any other study involving investigational drugs or devices
 
24. Severe illness, other than heart disease, which would limit survival to < 3 years
 
25. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities
 
26. Pregnancy
 
27. Patient unwilling or unable to comply with study requirements
 
28. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator